FDA — authorised 31 July 2018
- Marketing authorisation holder: SHIONOGI INC
- Status: approved
🇺🇸 Mulpleta in United States
FDA authorised Mulpleta on 31 July 2018
Marketing authorisations
FDA — authorised 31 July 2018
- Application: NDA210923
- Marketing authorisation holder: VANCOCIN ITALIA
- Indication: Type 1 - New Molecular Entity
- Status: approved
Mulpleta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Mulpleta approved in United States?
Yes. FDA authorised it on 31 July 2018; FDA authorised it on 31 July 2018.
Who is the marketing authorisation holder for Mulpleta in United States?
SHIONOGI INC holds the US marketing authorisation.